Nuzenio

This Lyell Immunopharma

This Lyell Immunopharma news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.stsimplywall.st · Sat, 08 Aug 2026 13:28:42 GMT Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingViewTradingView · Thu, 06 Aug 2026 20:35:29 GMT BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingViewTradingView · Thu, 06 Aug 2026 20:06:14 GMT Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 20:05:00 GMT This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursda - BenzingaBenzinga · Thu, 06 Aug 2026 14:12:18 GMT Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.comInvesting.com · Wed, 05 Aug 2026 21:33:52 GMT Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingViewTradingView · Wed, 29 Jul 2026 06:51:09 GMT Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT

Timeline

Sat, 08 Aug 2026 13:28:42 GMTPossible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - simplywall.st

Thu, 06 Aug 2026 20:35:29 GMTLyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView

Thu, 06 Aug 2026 20:06:14 GMTBRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingView

Thu, 06 Aug 2026 20:05:00 GMTLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - GlobeNewswire

Thu, 06 Aug 2026 14:12:18 GMTThis Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursda - Benzinga

Wed, 05 Aug 2026 21:33:52 GMTStifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.com

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Lyell Immunopharma8 live mentions Inc4 live mentions Investing3 live mentions LYEL3 live mentions Possible Signal As2 live mentions Lyell Immunopharma Insiders2 live mentions Sell US2 live mentions In Stock2 live mentions Operating Expenses USD2 live mentions Financial Results2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for This Lyell Immunopharma.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.